View Item 

Show simple item record

Skin Gene Expression Correlates of Severity of Interstitial Lung Disease in Systemic Sclerosis
dc.contributor.authorAssassi, Shervinen_US
dc.contributor.authorWu, Minghuaen_US
dc.contributor.authorTan, Filemon K.en_US
dc.contributor.authorChang, Jeffreyen_US
dc.contributor.authorGraham, Tiffany A.en_US
dc.contributor.authorFurst, Daniel E.en_US
dc.contributor.authorKhanna, Dineshen_US
dc.contributor.authorCharles, Julioen_US
dc.contributor.authorFerguson, Emma C.en_US
dc.contributor.authorFeghali‐bostwick, Carolen_US
dc.contributor.authorMayes, Maureen D.en_US
dc.date.accessioned2013-11-01T19:00:48Z
dc.date.available2015-01-05T13:54:44Zen_US
dc.date.issued2013-11en_US
dc.identifier.citationAssassi, Shervin; Wu, Minghua; Tan, Filemon K.; Chang, Jeffrey; Graham, Tiffany A.; Furst, Daniel E.; Khanna, Dinesh; Charles, Julio; Ferguson, Emma C.; Feghali‐bostwick, Carol ; Mayes, Maureen D. (2013). "Skin Gene Expression Correlates of Severity of Interstitial Lung Disease in Systemic Sclerosis." Arthritis & Rheumatism 65(11): 2917-2927.en_US
dc.identifier.issn0004-3591en_US
dc.identifier.issn1529-0131en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/100260
dc.publisherWiley Periodicals, Inc.en_US
dc.titleSkin Gene Expression Correlates of Severity of Interstitial Lung Disease in Systemic Sclerosisen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelGeriatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/100260/1/art38101.pdf
dc.identifier.doi10.1002/art.38101en_US
dc.identifier.sourceArthritis & Rheumatismen_US
dc.identifier.citedreferenceTusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001; 98: 5116 – 21.en_US
dc.identifier.citedreferenceTashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1‐year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176: 1026 – 34.en_US
dc.identifier.citedreferenceAssassi S, Sharif R, Lasky RE, McNearney TA, Estrada YM, Draeger HT, et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010; 12: R166.en_US
dc.identifier.citedreferenceHsu E, Shi H, Jordan RM, Lyons‐Weiler J, Pilewski JM, Feghali‐Bostwick CA. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum 2011; 63: 783 – 94.en_US
dc.identifier.citedreferenceGardner H, Shearstone JR, Bandaru R, Crowell T, Lynes M, Trojanowska M, et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006; 54: 1961 – 73.en_US
dc.identifier.citedreferenceWhitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, et al. Systemic and cell type‐specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 2003; 100: 12319 – 24.en_US
dc.identifier.citedreferenceMilano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connolly MK, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 2008; 3: e2696.en_US
dc.identifier.citedreferenceGreenblatt MB, Sargent JL, Farina G, Tsang K, Lafyatis R, Glimcher LH, et al. Interspecies comparison of human and murine scleroderma reveals IL‐13 and CCL2 as disease subset‐specific targets. Am J Pathol 2012; 180: 1080 – 94.en_US
dc.identifier.citedreferenceSargent JL, Milano A, Bhattacharyya S, Varga J, Connolly MK, Chang HY, et al. A TGFβ‐responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 2010; 130: 694 – 705.en_US
dc.identifier.citedreferenceKhanna D, Saggar R, Mayes MD, Abtin F, Clements PJ, Maranian P, et al. A one‐year, phase I/IIa, open‐label pilot trial of imatinib mesylate in the treatment of systemic sclerosis–associated active interstitial lung disease. Arthritis Rheum 2011; 63: 3540 – 6.en_US
dc.identifier.citedreferenceSubcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581 – 90.en_US
dc.identifier.citedreferenceHankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159: 179 – 87.en_US
dc.identifier.citedreferenceFurst D, Khanna D, Matucci‐Cerinic M, Clements P, Steen V, Pope J, et al. Systemic sclerosis—continuing progress in developing clinical measures of response. J Rheumatol 2007; 34: 1194 – 200.en_US
dc.identifier.citedreferenceClements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281 – 5.en_US
dc.identifier.citedreferenceLivak KJ, Schmittgen TD. Analysis of relative gene expression data using real‐time quantitative PCR and the 2 −ΔΔC T method. Methods 2001; 25: 402 – 8.en_US
dc.identifier.citedreferenceHamaguchi Y, Fujimoto M, Matsushita T, Hasegawa M, Takehara K, Sato S. Elevated serum insulin‐like growth factor (IGF‐1) and IGF binding protein‐3 levels in patients with systemic sclerosis: possible role in development of fibrosis. J Rheumatol 2008; 35: 2363 – 71.en_US
dc.identifier.citedreferenceCarulli MT, Ong VH, Ponticos M, Shiwen X, Abraham DJ, Black CM, et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum 2005; 52: 3772 – 82.en_US
dc.identifier.citedreferenceBlann AD, Constans J, Carpentier P, Renard M, Satger B, Guerin V, et al. Soluble P selectin in systemic sclerosis: relationship with von Willebrand factor, autoantibodies and diffuse or localised/limited disease. Thromb Res 2003; 109: 203 – 6.en_US
dc.identifier.citedreferencePatel KD, Moore KL, Nollert MU, McEver RP. Neutrophils use both shared and distinct mechanisms to adhere to selectins under static and flow conditions. J Clin Invest 1995; 96: 1887 – 96.en_US
dc.identifier.citedreferenceHasegawa M, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K, Sato S. Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol 2011; 30: 231 – 7.en_US
dc.identifier.citedreferenceInoshima I, Kuwano K, Hamada N, Hagimoto N, Yoshimi M, Maeyama T, et al. Anti‐monocyte chemoattractant protein‐1 gene therapy attenuates pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2004; 286: L1038 – 44.en_US
dc.identifier.citedreferenceAmjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, et al, for the Investigators of the D‐Penicillamine, Human Recombinant Relaxin, and Oral Bovine Type I Collagen Clinical Trials. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double‐blind, randomized controlled trials. Arthritis Rheum 2009; 60: 2490 – 8.en_US
dc.identifier.citedreferenceFarina G, Lafyatis D, Lemaire R, Lafyatis R. A four‐gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2010; 62: 580 – 8.en_US
dc.identifier.citedreferenceHinchcliff M, Huang CC, Wood TA, Matthew MJ, Martyanov V, Bhattacharyya S, et al. Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol 2013; 133: 1979 – 89.en_US
dc.identifier.citedreferenceSteen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972‐2002. Ann Rheum Dis 2007; 66: 940 – 4.en_US
dc.identifier.citedreferenceTyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809 – 15.en_US
dc.identifier.citedreferenceTashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655 – 66.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
art38101.pdf
Size:
1.202MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.